
    
      This is a prospective open label, single center pilot trial that will evaluate regadenoson
      compared to Adenoscan® to be given IV in the assessment of Fractional Flow Reserve. Forty
      eight subjects will be enrolled and get Adenoscan® administered via IV followed by
      Regadenoson IV.
    
  